Medicus Pharma Ltd Ordinary Shares MDCX 深 沪
等待开盘 12-29 09:30:00 美东时间
1.565
+0.015
+0.97%
华盛通- 最 高1.60
- 今 开1.57
- 成交量 24.65万股
- 最 低 1.53
- 昨 收 1.55
- 总市值 2788.25万
- 52周最高 8.94
- 市盈率 静 --
- 换手率 1.38%
- 52周最低 1.49
- 委 比 -29.19%
- 总股本 1781.63万
- 历史最高 8.94
- 量 比 0.73
- 振 幅 4.52%
- 历史最低 1.49
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:MDCX) with a Buy and maintains $27 price target.
12-15 21:16
Medicus Pharma Elevates President Carolyn Bonner to CFO as Co-Founder Jim Quinlan Steps Down for Health Reasons
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics
12-01 20:37
Medicus Pharma Seeks Fast-Track FDA Voucher for New Skin Cancer Treatment
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
11-17 20:35
Medicus Pharma Q3 EPS $(1.12) Misses $(0.29) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.29) by 286.21 percent. This is a 366.67 percent decrease over losses of $(0.24) per share
11-15 06:01
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:MDCX) with a Buy and maintains $27 price target.
11-13 21:10
Medicus Pharma Partners With Gorlin Syndrome Alliance To Enhance Access To SKINJECT For Gorlin Syndrome Patients
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
10-29 19:34
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Medicus Pharma collaborates with Gorlin Syndrome Alliance to advance access to SKINJECT™, a novel therapy for Gorlin syndrome patients with basal cell carcinomas. SKINJECT™ uses microneedle arrays to deliver doxorubicin, targeting localized treatments for skin cancers. The collaboration aims to establish an Expanded Access IND Program, collecting real-world data to support future regulatory filings. Gorlin syndrome affects 1 in 31,000 people, cau...
10-29 11:30
Medicus Pharma Begins UAE Trial for Non-Invasive Skin Cancer Treatment
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
10-22 19:35
